Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DPY30 domain-containing protein 2 (DYDC2) encodes a member of the DPY30 domain protein family. The protein has not been characterized with respect to molecular function, interacting partners, or pathways. Unlike DPY30, an essential core regulator of histone H3K4 methylation and gene expression, DYDC2's biological role in human cells is not defined. The gene locus overlaps with a related gene (possibly DYDC1) on the opposite strand, but its transcript variants and tissue expression pattern remain poorly documented. There is insufficient evidence that DYDC2 functions as a receptor, enzyme, transcription factor, or other canonical drug target; nor is it implicated in disease by mechanism. Most literature on the DPY30 domain concerns its structural role in chromatin remodeling complexes and transcriptional activation (for DPY30, not DYDC2). No drugs, biomarkers, or safety issues are known.
None identified for DYDC2, but for DPY30 domain generally: associated with histone methyltransferase complexes. Not applicable to DYDC2 specifically.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DPY30 domain-containing protein 2 (DYDC2).